Previously, a sub-analysis of the N9831 trial suggested that patients with resected HER2-positive BC, treated with trastuzumab containing chemotherapy may exhibit an impaired prognosis if FISH HER2/CEP17 ratios were ≥15 [32]. Here, ERBB2 is linked to breast cancer.